KBP s COVID-19 vaccine advances to human clinical trials messenger-inquirer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from messenger-inquirer.com Daily Mail and Mail on Sunday newspapers.
A biopharmaceutical company owned by Reynolds American Inc. has gained Food and Drug Administration approval to begin a Phase 1 clinical trial stage in humans for a potential coronavirus vaccine.
Kentucky BioProcessing LLC, based on Owensboro, Ky., has been infecting fast-growing tobacco plants this year with a genetically modified coronavirus to see if the plants can produce antibodies for a possible vaccine.
A pre-clinical trial testing began in April and was expected to take two months.
British American Tobacco Plc, the parent company of Reynolds, said Wednesday the vaccine candidate was approved for its Investigational New Drug application.
Enrollment of about 180 adults is expected to begin shortly.
“What Fruit It Bears” is an exhibition project presenting works by artists whose practices are radically individual defying categorization, and yet together represent the present time.
This exhibition presents approaches to figuration, which seek equilibrium in understanding both oneself and the collective path forward.
Many of these works were made this year and respond to the tumult that every individual has experienced globally.
As one emerges from isolation, this presentation proposes a future in which personal identity is both celebrated and supported by a renewed appreciation for community and solidarity.
The selected works explore the force of the unutterable and the variances in what one does not have language to express. Employing diverse languages of figuration, text and abstraction, the artists presently expose the body, skin and landscape as contested sites, located across both natural and cultural categories.